On November 21st, Baekje announced that it had reached a cooperation agreement with Ensem Therapeutics to introduce the CDK2 inhibitor ETX-197, which the latter is about to submit for IND (drug clinical trials).
According to the terms of the agreement, Ensem will receive a down payment and is entitled to additional payments based on specific research and development, registration, and commercialization milestones achieved, with a total transaction amount of $1.33 billion. In addition, Ensem will also have the right to receive graded sales royalties.
Ensem is a pioneering drug research and development company that leverages its unique Kinetic Ensemble& Reg; Develop innovative small molecule precise anticancer therapies on the technology platform. The CDK2 inhibitor ETX-197 is also Ensem's first pipeline.
Senior Vice President of Baekje Shenzhou Dr. Wang Lai, Global R&D Director, stated: "Baekje Shenzhou is committed to developing new molecules to improve the treatment pattern of cancer patients. At present, there is a huge and unmet clinical demand in the field of breast cancer. This cooperation coincides with our strategic focus in the field of breast cancer. Ensem's CDK2 inhibitor complements the CDK4 inhibitor independently developed by the company and in clinical phase 1, which is expected to improve the current CDK4/6 inhibitor in specific breast cancer patients Treatment effect, and strengthen our early research and development pipeline in the field of breast cancer and other solid tumors. We look forward to working with Ensem to promote this molecule into clinical practice in the near future